Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 4Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Metastatic HER2-positive Breast Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 7Oxaliplatin 6Cisplatin 5durvalumab 3130-nm albumin-bound paclitaxel 3pembrolizumab 2Leucovorin 2Drug Therapy 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1sintilimab 1pertuzumab 1anlotinib 1Trastuzumab 1Taxes 1Standard of Care 1Platinum 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Long-Term Synaptic Depression 1Irinotecan 1Folfox protocol 1Fluorouracil 1Everolimus 1Commerce 1Cholangiopancreatography, Endoscopic Retrograde 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Gallbladder Neoplasms × zanidatamab × Clear all
NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡